ArticleDiagnostic microbiology and infectious disease2013
An alternative in vitro drug screening test using Leishmania amazonensis transfected with red fluorescent protein.
Article in Diagnostic microbiology and infectious disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 50 citations in OpenAlex.
- Investigation of Viscoelastic Properties of Macrophage Membrane-Cytoskeleton Induced by Gold Nanorods in Leishmania Infection.Nanomaterials (Basel, Switzerland) · 2025Article
- The absence of eosinophils is associated with early metastatic lesions in Leishmania amazonensis-infected mice.Memorias do Instituto Oswaldo Cruz · 2024Article
- Leishmania amazonensis from distinct clinical forms/hosts has polymorphisms in Lipophosphoglycans, displays variations in immunomodulatory properties and, susceptibility to antileishmanial drugs.Cell biology international · 2022Article
- Oral and Intragastric: New Routes of Infection byPathogens (Basel, Switzerland) · 2022Article
- Reporter gene systems: A powerful tool forCurrent research in microbial sciences · 2022Article
- Novel 2D and 3D Assays to Determine the Activity of Anti-Leishmanial Drugs.Microorganisms · 2020Article
- Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis.International journal for parasitology. Drugs and drug resistance · 2019Review
- Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis.International journal for parasitology. Drugs and drug resistance · 2018Review
- Extracellular Vesicles Released byFrontiers in microbiology · 2018Article
- Use of Optical Imaging Technology in the Validation of a New, Rapid, Cost-Effective Drug Screen as Part of a TieredAntimicrobial agents and chemotherapy · 2017Article
- Achievement of constitutive fluorescent pLEXSY-egfp Leishmania braziliensis and its application as an alternative method for drug screening in vitro.Memorias do Instituto Oswaldo Cruz · 2017Article
- Construction of Two mCherry Plasmids (pXG-mCherry) for TransgenicJournal of parasitology research · 2017Article
- In Vitro Infectivity Assessment by Drug Susceptibility Comparison of Recombinant Leishmania major Expressing Enhanced Green Fluorescent Protein or EGFP-Luciferase Fused Genes with Wild-Type Parasite.The Korean journal of parasitology · 2015Article
- Infrared fluorescent imaging as a potent tool for in vitro, ex vivo and in vivo models of visceral leishmaniasis.PLoS neglected tropical diseases · 2015Article
- INsPECT, an open-source and versatile software for automated quantification of (Leishmania) intracellular parasites.PLoS neglected tropical diseases · 2014Article
- In vitro screening test using Leishmania promastigotes stably expressing mCherry protein.Antimicrobial agents and chemotherapy · 2014Article
- Cytotoxicity and In Vitro Antileishmanial Activity of Antimony (V), Bismuth (V), and Tin (IV) Complexes of Lapachol.Bioinorganic chemistry and applications · 2013Article
- Parasite Burden Measurement in theIranian journal of parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
Fluorescent and colorimetric reporter genes are valuable tools for drug screening models, since microscopy is labor intensive and subject to observer variation. In this work, we propose a fluorimetric method for drug screening using red fluorescent parasites. Fluorescent Leishmania amazonensis were developed after transfection with integration plasmids containing either red (RFP) or green fluorescent protein (GFP) genes. After transfection, wild-type (LaWT) and transfected (LaGFP and LaRFP) parasites were subjected to flow cytometry, macrophage infection, and tests of susceptibility to current antileishmanial agents and propranolol derivatives previously shown to be active against Trypanosoma cruzi. Flow cytometry analysis discriminated LaWT from LaRFP and LaGFP parasites, without affecting cell size or granulosity. With microscopy, transfection with antibiotic resistant genes was not shown to affect macrophage infectivity and susceptibility to amphotericin B and propranolol derivatives. Retention of fluorescence remained in the intracellular amastigotes in both LaGFP and LaRFP transfectants. However, detection of intracellular RFP parasites was only achieved in the fluorimeter. Murine BALB/c macrophages were infected with LaRFP parasites, exposed to standard (meglumine antimoniate, amphotericin B, Miltefosine, and allopurinol) and tested molecules. Although it was possible to determine IC(50) values for 4 propranolol derivatives (1, 2b, 3, and 4b), all compounds were considered inactive. This study is the first to develop a fluorimetric drug screening test for L. amazonensis RFP. The fluorimetric test was comparable to microscopy with the advantage of being faster and not requiring manual counting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.